Chonnam National University Hospital succeeded in introducing Impella for the first time in the country...Proof of improved survival of acute myocardial infarction
Dec 01, 2025
Chonnam National University Hospital (Hospital Director Jung) successfully performed the first procedure in the country, opening a new chapter in the treatment of severe heart disease in the region.
Chonnam National University Hospital is one of the first institutions in Korea to introduce Impella along with Samsung Seoul Hospital and Bundang Seoul National University Hospital, and has continued to experience successful procedures since the beginning of its introduction. The procedure was carried out with the participation of an intervention team consisting of professors Ahn Young-geun, Kim Joo-han, Hong Young-joon, Shim Doo-sun, Kim Min-cheol, Lee Seung-heon, Ahn Joon-ho, Hyundai Yong, Oh Seok and Lim Yong-hwan of the Department of Circulatory Medicine.
Impella is a mechanical circulation device that assists left ventricular function, and has been widely used in major developed countries such as Europe and the United States for more than 20 years. It was officially introduced as a new medical technology in Korea in the second half of 2025, and is recognized as the only mechanical circulation device that improves survival rates, especially in patients with cardiac shock in acute myocardial infarction. The mortality rate of acute myocardial infarction combined with cardiac shock reached 40-50%, forcing Korea to rely on drug therapy or ECMO.
Impella is a principle that aids heart function by inserting a thin tube into the left ventricle through the femoral artery. Through this, it plays a crucial role in reducing the burden on the heart and reducing the burden on the left ventricle to increase the patient's chances of survival in an emergency situation of cardiac shock.
With the success of the first procedure, Chonnam National University Hospital has the foundation to provide faster and more effective treatment to patients with severe myocardial infarction in the region. In the future, we plan to actively utilize Impella to increase access to treatment within Golden Time and to improve patient survival.
Professor Ahn Young-geun, who successfully carried out the procedure after introducing Impella for the first time in the country, said, `Thanks to the efforts of related academic societies and the government, we can apply world-standard treatment to patients with acute myocardial infarction with cardiac shock.' Chonnam National University Hospital will do its best to save more patients' lives by expanding the use of Impella."
Chonnam National University Hospital is one of the first institutions in Korea to introduce Impella along with Samsung Seoul Hospital and Bundang Seoul National University Hospital, and has continued to experience successful procedures since the beginning of its introduction. The procedure was carried out with the participation of an intervention team consisting of professors Ahn Young-geun, Kim Joo-han, Hong Young-joon, Shim Doo-sun, Kim Min-cheol, Lee Seung-heon, Ahn Joon-ho, Hyundai Yong, Oh Seok and Lim Yong-hwan of the Department of Circulatory Medicine.
Impella is a mechanical circulation device that assists left ventricular function, and has been widely used in major developed countries such as Europe and the United States for more than 20 years. It was officially introduced as a new medical technology in Korea in the second half of 2025, and is recognized as the only mechanical circulation device that improves survival rates, especially in patients with cardiac shock in acute myocardial infarction. The mortality rate of acute myocardial infarction combined with cardiac shock reached 40-50%, forcing Korea to rely on drug therapy or ECMO.
Impella is a principle that aids heart function by inserting a thin tube into the left ventricle through the femoral artery. Through this, it plays a crucial role in reducing the burden on the heart and reducing the burden on the left ventricle to increase the patient's chances of survival in an emergency situation of cardiac shock.
With the success of the first procedure, Chonnam National University Hospital has the foundation to provide faster and more effective treatment to patients with severe myocardial infarction in the region. In the future, we plan to actively utilize Impella to increase access to treatment within Golden Time and to improve patient survival.
Professor Ahn Young-geun, who successfully carried out the procedure after introducing Impella for the first time in the country, said, `Thanks to the efforts of related academic societies and the government, we can apply world-standard treatment to patients with acute myocardial infarction with cardiac shock.' Chonnam National University Hospital will do its best to save more patients' lives by expanding the use of Impella."
|
This article was translated by Naver AI translator.
